Core Insights - The REVEAL-1 trial for elegrobart met its primary endpoint, demonstrating a proptosis responder rate of 54% for the Q4W regimen and 63% for the Q8W regimen, compared to 18% for placebo at week 24 [1] - The trial also showed a complete resolution of diplopia in 51% of patients treated with the Q4W regimen versus 16% for placebo, indicating good tolerability of elegrobart [2] Competitive Concerns - William Blair highlighted that the placebo-adjusted proptosis responder rates of 36% (Q4W) and 45% (Q8W) fell short of the expected 51%-73% range, suggesting that the stock price decline may be an overreaction [3] - Analyst Lachlan Hanbury-Brown noted that various factors contributed to the weaker placebo-adjusted change, and the stock is expected to recover as investors analyze the complete dataset [3] Cash Position and Pipeline - The REVEAL-2 study for chronic TED is on track to report topline data in Q2 2026, with a Biologics License Application (BLA) for elegrobart anticipated to be submitted to the FDA in Q1 2027 [4] - The company ended fiscal 2025 with $875 million in cash, which is projected to support its business plans until profitability, especially with expected revenues from elegrobart and veligrotug if approved [5] Competitive Landscape - Viridian Therapeutics shares experienced a significant decline of 38.26%, trading at $16.91 during premarket on Monday [6]

Core Insights - Kynam Capital Management reduced its stake in Viridian Therapeutics by 2,957,386 shares in Q4 2025, with an estimated transaction value of $81.11 million based on average pricing [2][4] - The value of Viridian's stake declined by $49.79 million at quarter-end, reflecting both trading and market price effects [2] - Viridian Therapeutics is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, particularly for thyroid eye disease [6][9] Company Overview - Current stock price of Viridian Therapeutics is $26.98, with a market capitalization of $2.8 billion [4] - The company reported a total revenue of $70.79 million and a net income loss of $342.6 million over the trailing twelve months [4] - Viridian's pipeline includes monoclonal antibody therapies targeting serious diseases, with a focus on thyroid eye disease [9] Financial Performance - Kynam Capital's stake in Viridian now represents 2.92% of its 13F reportable assets under management [8] - Viridian shares have increased by 76% over the past year, significantly outperforming the S&P 500's 15% gain during the same period [8] - The company is facing high research and development costs, nearing $339 million, with a full-year net loss of approximately $343 million [10] Upcoming Milestones - Viridian is approaching a critical period with a PDUFA date for veligrotug on June 30 and multiple Phase 3 readouts for VRDN-003 expected this year [10] - The company has a strong balance sheet with approximately $875 million in cash at year-end, which helps mitigate financial risks [10]

Summary of Viridian Therapeutics Conference Call Company Overview - **Company**: Viridian Therapeutics (NasdaqCM:VRDN) - **Industry**: Biotechnology, specifically focused on treatments for thyroid eye disease (TED) Key Points and Arguments 1. **Lead Program and Upcoming Milestones**: - Viridian's lead program, veligrotug, is expected to go commercial with a PDUFA date of June 30, 2026, following a successful BLA submission in 2025 [2][3] - The TED market is currently valued at $2 billion with only one product available [3] 2. **Clinical Trials and Data**: - Two Phase 3 readouts are anticipated within the next 12 months, one in Q1 and another in Q2 [2][4] - The first Phase 3 trial focuses on the active form of TED, while the second addresses the chronic form [5] 3. **Regulatory Designations**: - The Breakthrough Therapy designation has facilitated positive interactions with the FDA, enhancing the likelihood of priority review for the BLA [9][11] 4. **Market Readiness**: - The company is nearly 100% launch-ready, having built out its field force and market access teams ahead of the PDUFA date [12][14] 5. **Pricing Strategy**: - Pricing discussions with payers indicate potential parity pricing with Tepezza, allowing for a 10%-15% variance [17] - The pricing strategy will consider the full course of treatment, which consists of five infusions compared to Tepezza's eight [18] 6. **Target Patient Population**: - The current TED patient population is skewed towards active cases, but Viridian aims to capture chronic patients with robust clinical data [19][20] - There are approximately 2,000 core prescribers for IGF-1R therapies, providing a focused target for marketing efforts [22] 7. **Market Expansion with Subcutaneous (SubQ) Program**: - The SubQ program (elegrobart) is expected to expand the market by providing a self-administered option, improving access for patients who cannot easily reach infusion centers [45][46] - The anticipated market split in a mature setting is 70% SubQ and 30% IV [49] 8. **Competitive Landscape**: - Several competitors have faced challenges, with notable programs being terminated or showing mixed results [50][52] - Viridian's trials have been well-received, with high enrollment rates indicating strong patient demand [52] 9. **FcRn Portfolio**: - The FcRn portfolio offers strategic optionality, with two compounds in development that could provide differentiated treatment options in the future [54][55] 10. **TSHR-targeted Program**: - A new TSHR antibody program is in preclinical stages, with potential applications in both TED and Graves' disease [59][60] Additional Important Information - The company has successfully enrolled a significant number of patients in clinical trials, indicating strong interest and demand for IGF-1R therapies [52] - The competitive landscape has shifted favorably for Viridian, with fewer viable competitors in the TED space [53] - The company plans to file an IND for the TSHR program in Q4 2026, indicating ongoing innovation and development [60][64]

Core Insights - Viridian Therapeutics, Inc. (NASDAQ:VRDN) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - The company is preparing for a potential commercial launch of its treatment for thyroid eye disease in mid-2026, contingent on regulatory approval [2] - Recent earnings reports indicate a Q4 EPS of ($1.08), which was below the consensus estimate of ($1.00), and Q4 revenue of $132,000, significantly lower than the consensus of $15.75 million [4] Price Target Adjustments - RBC Capital has lowered its price target for Viridian Therapeutics to $42 from $45 while maintaining an Outperform rating, citing the company's positioning for a transition to commercial operations in 2026 [2] - Jefferies has raised its price target to $45 from $44, affirming a Buy rating, and noted that all key events are on track, with a focus on upcoming Phase 3 trial results [3] Company Developments - The company is advancing its pipeline with the BLA filing for veligrotug under Priority Review and a PDUFA target date set for June 30, 2026 [4] - The submission of the MAA to the EMA is aimed at expanding the global market opportunity for veligrotug [4] - Upcoming topline data for elegrobart from the REVEAL-1 trial is expected next month, which is crucial for establishing both veligrotug and elegrobart as foundational therapies for thyroid eye disease [4]

Company Overview - Viridian Therapeutics is a clinical-stage biotechnology company focused on developing innovative antibody-based therapies, particularly for thyroid eye disease [6] - The company utilizes monoclonal antibody engineering to advance its pipeline and address unmet medical needs in rare disorders [6] - As of February 17, 2026, Viridian's market capitalization is $2.30 billion, with a revenue of $70.79 million and a net income of -$301.97 million [4] Recent Developments - On February 17, 2026, Commodore Capital disclosed the sale of its entire 3,200,000-share position in Viridian Therapeutics, amounting to approximately $69.06 million [1][2] - This liquidation reduced Viridian's weighting in Commodore's portfolio from 3.4% to zero [7] - Following the sale, Viridian's shares were priced at $28.29, reflecting a 75% increase over the past year, outperforming the S&P 500 [7][10] Future Prospects - Viridian is entering 2026 with significant potential catalysts, including the FDA's acceptance of veligrotug's BLA for thyroid eye disease, with a PDUFA date set for June 30 [10] - The company has approximately $888 million in cash and investments, indicating a strong financial position to fund operations until profitability [10] - The removal of Commodore's stake may suggest a strategic shift towards other investments or a response to valuation considerations, as Viridian approaches a catalyst-heavy year [11]

Core Insights - Viridian Therapeutics is focused on creating best-in-class medicines for serious and rare diseases, with key priorities set for 2026, including pivotal data delivery and potential product launches [2][5][8]. Group 1: Product Development and Pipeline - The FDA has accepted the Biologics License Application (BLA) for veligrotug under Priority Review, with a target action date of June 30, 2026, indicating a significant need for new treatment options in Thyroid Eye Disease (TED) [5][8]. - Veligrotug has shown positive results in two large Phase 3 trials (THRIVE and THRIVE-2), demonstrating rapid treatment effects and durable responses in patients with active and chronic TED [5][8]. - The company is on track to submit a Marketing Authorization Application (MAA) to the European Medicines Agency in Q1 2026 [5]. - Topline data for elegrobart (VRDN-003) is expected in Q1 and Q2 2026 from ongoing Phase 3 trials (REVEAL-1 and REVEAL-2) [5][8]. - A new TSHR inhibitor program is being developed, with an Investigational New Drug (IND) application expected in Q4 2026 [5][9]. Group 2: Market Strategy and Commercialization - The U.S. TED market is valued at approximately $2 billion, with the company targeting around 2,000 core prescribers for its products [5][8]. - The commercial infrastructure for the veligrotug launch is anticipated to facilitate the launch of elegrobart, which is expected to be the only autoinjector for TED at the time of its launch [5][8][13]. - The company ended October 2025 with approximately $888 million in cash and investments, positioning it well to fund its business plans through profitability [12]. Group 3: Clinical Trials and Research - VRDN-006 has achieved proof-of-concept for IgG reduction in healthy volunteers, demonstrating its potential within the FcRn inhibitor class [5][9]. - VRDN-008's IND was submitted in December 2025, with Phase 1 healthy volunteer data expected in the second half of 2026 [12].

Pipeline and Milestones - Viridian aims to be a leading autoimmune company, starting with thyroid eye disease (TED)[6] - Viridian plans to submit a MAA for veligrotug in Q1 2026 and anticipates a PDUFA target date of June 30, 2026[19] - Topline data for REVEAL-1 (active TED) is expected in Q1 2026, and REVEAL-2 (chronic TED) in Q2 2026 for elegrobart[19] - An IND submission for an anti-TSHR subcutaneous product is anticipated in Q4 2026[10, 16, 19] - VRDN-008 healthy volunteer data is expected in 2H 2026[16, 19] Veligrotug (Anti-IGF-1R; Intravenous) - Veligrotug has a PDUFA target date of June 30, 2026, with Priority Review designation[10, 16, 18, 25] - In the THRIVE trial for active TED, veligrotug showed a 70% proptosis responder rate compared to 5% for placebo (p < 00001)[33, 95, 97] - In the THRIVE-2 trial for chronic TED, veligrotug showed a 56% proptosis responder rate compared to 8% for placebo (p < 00001)[35, 118] - 70% of proptosis responders in the THRIVE trial maintained their response at Week 52[33, 110, 111] Elegrobart (VRDN-003; Anti-IGF-1R; Subcutaneous) - Pivotal readouts for elegrobart in active TED REVEAL-1 study in Q1 2026 and chronic TED REVEAL-2 study in Q2 2026[10] - Phase 1 data showed an extended half-life of 40-50 days and approximately 4-fold increase in IGF-1 levels with subcutaneous elegrobart[134, 135] Financials - Viridian had $888 million in cash as of October 31, 2025, which, along with near-term DRI milestones and anticipated future revenues, is expected to fund current business plans through profitability[20] - The company secured access to up to approximately $900 million in capital in 2025[13] Market Opportunity - The annualized TED market is approximately $2 billion[10, 43] - The market sizes of MG and CIDP alone are projected to be over $112 billion by 2030[84, 85]

Core Insights - Argenx SE has decided to discontinue the Phase 3 UplighTED studies for efgartigimod in adults with moderate to severe thyroid eye disease (TED) based on an Independent Data Monitoring Committee's recommendation due to futility [1][3] Study Design and Outcomes - The Phase 3 studies aimed to evaluate the efficacy, safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of efgartigimod PH20 SC in adult participants with TED, with the primary endpoint being the percentage of participants who were proptosis responders at week 24 [4] - Key secondary endpoints included changes in proptosis measurement, total Graves' Orbitopathy Quality of Life (GO-QoL) score, and the percentage of participants with resolution of diplopia at week 24 [5] Safety Profile - Efgartigimod demonstrated a favorable safety and tolerability profile, with no new safety signals identified during the trials [2] Market Implications - The discontinuation of the studies raises questions about the biological differences between TED and related conditions, as noted by analysts [6] - Amgen's Tepezza is currently the only FDA-approved drug for TED, while Viridian Therapeutics' veligrotug is expected to receive FDA approval in 2026 [7] - Analyst projections for peak TED sales for Vyvgart are estimated at $550 million, assuming a 60% probability of success, indicating a secondary opportunity compared to larger programs [7] - Following the news, Argenx shares fell by 4.86% to $835.31 [8]

Summary of Viridian Therapeutics Conference Call Company Overview - **Company**: Viridian Therapeutics - **Industry**: Biopharmaceuticals focusing on autoimmune diseases - **Key Participants**: Steve Mahoney (CEO), Tony Castianos (Chief Commercial Officer), Shan Wu (Chief Business Officer) [1][2] Core Points and Arguments Autoimmune Portfolio - Viridian is advancing an autoimmune portfolio with a focus on thyroid eye disease (TED), a market valued at approximately $2 billion in the U.S. [2] - The company has submitted a Biologics License Application (BLA) for its lead product, which has received breakthrough therapy designation from the FDA [4][2]. Market Dynamics - There is currently one competitor in the TED market, Tepezza, marketed by Amgen, which has shown a return to growth with sales of $560 million in the last quarter [10][11]. - The TED market consists of about 500,000 patients in the U.S., with 200,000 having moderate to severe forms of the disease [10][7]. Product Differentiation - Viridian's product, veligrotug, is expected to have a more favorable dosing regimen compared to Tepezza, requiring five infusions over three months versus eight infusions over five months for Tepezza [15][14]. - The onset of action for veligrotug is anticipated to be quicker, with significant proptosis response observed after just one infusion [15][16]. Clinical Data and Expectations - Phase three data from the THRIVE program indicates strong efficacy, with a proptosis response rate expected to meet or exceed the efficacy bar set by Tepezza [30][29]. - The company plans to launch with both active and chronic data in its label, which is a strategic advantage over Tepezza [17][16]. FCRN Portfolio - Viridian is also developing programs in the FCRN space, with two lead programs (006 and 008) targeting large markets projected to exceed $10 billion by 2030 [31][32]. - The company is focused on low-cost optionality in its FCRN portfolio, with ongoing studies to validate the efficacy and safety of its candidates [33][35]. Financial Position - Viridian recently announced a royalty deal with DRI, which is seen as a validation of its business model and does not encumber its lead products [37][38]. - The company expects to reach break-even and profitability, regardless of the FDA's review outcome [38][39]. Additional Insights - The TED market is characterized as a new start market, allowing for rapid adoption of new therapies without the need to switch patients from existing treatments [11][12]. - The concentration of prescribers in the TED market (approximately 2,000 core prescribers) allows for targeted commercial strategies [12][10]. - The company has engaged with over 500 key opinion leaders (KOLs) in October alone, indicating proactive market preparation [20][19]. This summary encapsulates the key points discussed during the conference call, highlighting the strategic positioning of Viridian Therapeutics within the biopharmaceutical industry, particularly in the treatment of autoimmune diseases.

Core Insights - Viridian Therapeutics, Inc. (NASDAQ:VRDN) is a biotechnology company focused on developing treatments for rare diseases, with RBC Capital setting a price target of $45, indicating a potential increase of about 63.64% from its current price of $27.50, reflecting strong confidence in the company's future performance [1][5] Financial Position - Viridian is positioned for profitability in 2026 due to successful financing transactions that have eliminated the need for further share dilution, which is a positive sign for investors [2][5] - The current stock price of VRDN is $27.50, showing a 12.61% increase or $3.08, with a market capitalization of approximately $2.23 billion and a trading volume of 4.86 million shares today [4] Competitive Landscape - The competitive landscape is shifting as Roche's Enspryng (satralizumab) has shown disappointing phase 3 results in treating thyroid eye disease, which reduces competitive pressure on Viridian's veligrotug and VRDN-003, potentially enhancing its market position and increasing market share in this therapeutic area [3][5]